

Immunotherapy in Gastrointestinal Cancer

Perspectives of EORTC, National Groups and Mainz University

Date: Friday 07 to Saturday 08 November 2014

Venue: Favorite Parkhotel Mainz, Karl-Weiser-Strasse 1, 55131 Mainz, Germany
Telephone: +49 (0) 6131-80150
Homepage: www.favorite-mainz.de
Please use the code "EORTC Meeting" for your reservation of a room

Contact: University Medical Center Mainz, 1st Department of Internal Medicine
Langenbeckstrasse 1, 55131 Mainz, Germany
Telephone: +49 (0) 6131-176076, Tanja Bender
E-Mail: tanja.bender@unimedizin-mainz.de
moehler@mail.uni-mainz.de

Please register under:

http://www.eortc.be/services/forms/GI/GI_Immunotherapy_meeting_Mainz.asp

Structure:

Friday	12.00 – 19.15	Presentations and discussions
Saturday	08.30 – 12.30	Presentations, workshop and discussions

Aim: Presentation and Discussion of new Immunotherapeutic Agents for Clinical Studies in GI Cancer

Outcome:


- ✓ notion of immunological agents and strategies in the near future
- ✓ notion of clinical study designs for testing immunotherapy in GI cancer
- ✓ notion of scientific and logistic aspects of translational research in clinical trials using immunotherapy
- ✓ paper for publication (Target EJC or Frontiers in Immunology)

Program Committee:

Markus Moehler
Manfred Lutz
Theo Ruers

Local Organization:

Markus Moehler
Tanja Bender
Ann Marinus
Vinciane Vincx



Program Friday 7th November:

- | | |
|---------------|--|
| 11.30 - 12.00 | Get Together and Lunch
Welcome Arnaud Roth, European chairman of EORTC GI group
Prof. Förstermann, Dean of Mainz University
Introduction to Program Markus Moehler |
| 12.10 - 13.10 | Basics of Tumor Immunology
Chairs: Michel Ducreux, Daniela Aust
Recruiting of the patients' anti-tumor T-cell repertoire
Thomas Wölfel
Context-specific features of Treg function and control
Hans- Jörg Schild
Viral vector based approaches in anti-tumor therapy
Hildegard Büning |
| 13.10 – 14.20 | State of the Art: Immune Therapy in GI Cancers
Chairs: Hauke Lang, Jens Marquardt
Do immune therapies require other RECIST criteria, endpoints or study statistics?
Murielle Mauer
Overview of Current Studies (EORTC and national groups)
Markus Moehler and Christoph Schimanski
Marc Peeters (antibodies)
Sandrine Faivre (hepatobiliary tumors) |
| 14.20-15.00 | Coffee break |
| 15.00-16.00 | Translational Research for Industry and Independent Groups
Chairs: Annegret Kuhn, Krzysztof Jeziorski
Assessment of immune cell subsets to guide progress of RNA-based immunotherapies
Cedrik Britten
NGS for immunotherapeutic trials
John Castle, TRON
TNFA as marker for activity of tumor specific cytotoxic T cells in colon cancer
Christoph Reißfelder |
| 16.00-17:00 | Pipeline discussion
Chairs: Daniela Aust, Doro Wagner
Angiogenesis Inhibitors and immune therapeutic agents
Florin Sirzen, Roche
N.N., Lilly
Thomas Felzmann, Activartis |
| 17.00-18.00 | Oncolytic Viruses as Immunotherapy
Chairs: Jean Rommelaere, Uli Lauer
Delphine Agathon, Jennerex/ Transgene
Oncolytic immunotherapy with a genetically modified virus in malignant melanoma
Juergen Becker, for Amgen
Phase I Study on Virotherapy of peritoneal carcinomatosis
Uli Lauer, Genelux
Phase I of Parvovirus H1
Karsten Geletneky |
| 19.00-22.00 | Dinner and social event: All speakers, guests and participants invited. |

Saturday 8th November:

08.30 – 09.15	Immune Infiltration Tools and Clinical Importance Chairs: Rupert Langer, Joseph Rüschhoff Gastric Cancer <i>Heike Grabsch</i> Evaluation of immune response in resectable colorectal liver metastases (EORTC 40983) <i>Catherine Julie</i> Regression of grading after chemo- or immunotherapy - does it include immune cells? <i>Rupert Langer</i>
09.30-10.30	Optimal Study Design and Translational Research* Chairs: Zoran Petrovic , Matthias Ebert Primary tumor vs metastases: infiltrating immune cell phenotypes and cytokines Immune Response: Maintenance in colorectal cancer <i>Niels Halama</i> Markers in IHC for vaccines <i>Daniela Aust</i> Local Ablation in hepatobiliary cancers and liver metastases <i>Theo Ruers</i> The “Mainz” way from bench to bedside: how to construct translational environment <i>Özlem Tureci</i>
10.15-11.15	Pipeline discussion Chairs: Stephan Grabbe or Florian Lordick Checkpoint Inhibitors and Vaccines <i>N.N., BMS</i> <i>Markus Moehler, for MSD</i> <i>Marnix Bosch, Northwest Biotherapeutics</i>
11.15-11:30	Coffee Break
11.30-12.00	Meeting of task forces** Task Force Gastric: <i>Dorothea Wagner</i> Task Force Colorectal: <i>Michel Ducreux</i> Task Force Pancreatic: <i>Manfred Lutz</i> Task Force Hepatobiliar: <i>Markus Moehler</i>
12.00-12.30	Reports from Task Forces and EORTC Future Directions Chairs + Conclusions: <i>Arnaud Roth, Michel Ducreux</i> Documentation: <i>Anne-Sophie Govaerts, Violaine Francois</i>
12.30	Lunch and Farewell <i>Markus Moehler, Daniela Aust</i>

- * should end in at least 3 recommendations for further potential projects
- ** should end in potential basic study design and recommendations for translational research.

We would like to thank the following firms for the sponsoring of the meeting:

Gold Sponsor

Amgen GmbH (3,000 € for advertising purposes)

MSD Sharp & Dohme GmbH (2,000 € for booth hire)

Roche Pharma AG (2,500 € for booth hire)

Silver Sponsor

Merck Serono GmbH (1,500 € for booth hire)

Bronze Sponsor

Bayer Vital GmbH (400 € for advertising purposes)